Final decision from the European Commission is anticipated within the coming months
India has taken the lead in recognising NAFLD as a major non-communicable disease
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role
Dyslipidemia is a critical risk factor for cardiovascular diseases
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
WINREVAIR is a breakthrough biologic for this rare, progressive disease
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
Subscribe To Our Newsletter & Stay Updated
